Naïve patients treated with faricimab showed superior improvement in VA and CMT with marginal significance, indicating that treatment with faricimab at the initial stages of neovascularization may change the course of the nAMD and potentially improve visual prognosis.
← all excerpts
Short term real-world effectiveness of faricimab in neovascular age-related macular degeneration patients in the Republic of Korea.
1
—
—